Author name: cmatranga@macdougall.bio

Press Release — Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time —Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the […]

Press Release Lead clinical asset AZR-MD-001 for Meibomian gland dysfunction to advance through registration study Meibomian gland dysfunction is the leading cause of Dry Eye Disease, a condition known to affect more than 30 million adults in the United States alone Financing also will support development of pipeline of new chemical entities in pre-clinical through

Press Release — Charles Bosworth from Allergan named as Chief Medical Officer to drive clinical strategy — TEL AVIV, Israel–Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), today announced it has completed a $16 million Series B funding round led by a syndicate of OrbiMed, TPG Biotech